Faricimab demonstrated short-term improvements in visual and anatomical outcomes for nAMD patients switching from other anti-VEGF therapies. The study showed reductions in central macular thickness, ...
Most retina specialists use a treat-and-extend approach for wet age-related macular degeneration (AMD), whereby anti–vascular endothelial growth factor (VEGF) injections are performed until the retina ...
Faricimab increased treatment intervals and decreased CST in previously treated nAMD patients, but BCVA remained unchanged. The study included 88 eyes from 73 patients, with a mean follow-up of 30.1 ...
BARCELONA, Spain — Early findings from a real-world study of the dual-action antibody faricimab have shown sustained improvement in visual acuity and key biomarkers of retinal anatomy, with no new ...
Geographic atrophy due to age-related macular degeneration (AMD) is the leading cause of irreversible blindness and affects more than 5 million persons worldwide. No therapies to restore vision in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results